Recent advances in small molecular near-infrared fluorescence probes for a targeted diagnosis of the Alzheimer disease
Nowadays, it is still quite challenging to achieve an early diagnosis of the Alzheimer disease (AD) in clinics. The burgeoning near-infrared fluorescence (NIRF) imaging fulfills the requirements for a precise diagnosis with good sensitivity and a high signal-to-background ratio and offers opportunit...
Saved in:
| Published in | Analyst (London) Vol. 147; no. 21; pp. 471 - 4723 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Royal Society of Chemistry
24.10.2022
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | Nowadays, it is still quite challenging to achieve an early diagnosis of the Alzheimer disease (AD) in clinics. The burgeoning near-infrared fluorescence (NIRF) imaging fulfills the requirements for a precise diagnosis with good sensitivity and a high signal-to-background ratio and offers opportunities for the efficient AD diagnosis. As the pathogenesis of AD is quite complex, there is an ongoing exploration of advanced probes to specifically target AD biomarkers (
e.g.
, amyloid-
β
(A
β
) plaques, neurofibrillary tangles, viscosity, peroxynitrite (ONOO
−
), reactive oxygen species, and methylglyoxal). To this end, a great number of small molecular fluorescent probes with good water solubility, blood-brain barrier crossing capability, and ease in tuning photophysical and biological properties have been studied for the AD diagnosis. Herein, we systematically update the progress of NIRF AD probes in the last three years. The special focus is on the mechanisms for the targeted diagnosis and the relationship between the structure and properties of the probes. Importantly, NIRF probes with complementary functions such as dual-responsiveness and multimodal imaging and even therapeutics are discussed. Moreover, the challenges and perspectives of the AD probes are briefly elucidated. We hope that this review provides guidance for researchers and expedites the preclinical and clinical study of the NIRF AD probes.
Near-infrared small molecular fluorescence probes for targeted diagnosis of Alzheimer's disease. |
|---|---|
| Bibliography: | Wang Jingjing is currently a research assistant at the School of Science, Harbin Institute of Technology (Shenzhen). She earned her Bachelor's and Master's of Philosophy degrees from the Huanghe Science and Technology College University and Zhengzhou University, respectively. Her current research focuses on the development of nanomedicines for brain disease imaging and therapy. Dr Yuanfei Deng is currently acting as Director of the Institute of Geriatric Medicine, Peking University Shenzhen Hospital, China. He obtained his Master of Neurology degree from Sun Yat-sen University. Dr Deng has been engaged in clinical work for more than thirty years. His current research focuses on neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and dystonia. Dr Bing Guo is currently acting as an associate professor at the School of Science, Harbin Institute of Technology (Shenzhen), China. He earned his Bachelor and Master of Philosophy degrees from Zhengzhou University and Hong Kong Polytechnic University, respectively. Dr Guo completed his Ph.D. study and postdoctoral training at the National University of Singapore. His current research focuses on the development of organic materials for molecular imaging probes and nanomedicines. Dr Genwen Hu is currently acting as Associate Chief Physician in the Radiology Department of Shenzhen People's Hospital. He earned his Bachelor and Master of Philosophy degrees from the Nanchang University and the Jinan University, respectively. Dr Hu completed his PhD study and postdoctoral training at Southern Medical University and Jinan University. He is a tutor for postgraduates majoring in imaging medicine and nuclear medicine at Jinan University and Southwest Medical University. His current research focuses on the development of nanoprobes for disease imaging. Yue Liu is currently a Master's student at the School of Science, Harbin Institute of Technology (Shenzhen). She earned her Bachelor's degree from Hunan University. Her current research focuses on the development of molecular imaging probes and nanomedicines. Danping Zhuang is currently a Master's student at Jinan University. She earned her Bachelor's degree from the Guangzhou Medical University. She is working under the supervision of Professor Dr Genwen Hu, Jinan University. Her current research interest focuses on the development of nanoprobes for disease imaging. ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ISSN: | 0003-2654 1364-5528 |
| DOI: | 10.1039/d2an01327d |